(ATEC) Alphatec Holdings - Overview
Stock: Spinal Implants, Surgical Instruments, Biologics, Navigation
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 61.2% |
| Relative Tail Risk | -16.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.54 |
| Alpha | 3.48 |
| Character TTM | |
|---|---|
| Beta | 0.699 |
| Beta Downside | 0.206 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.51% |
| CAGR/Max DD | 0.00 |
Description: ATEC Alphatec Holdings January 14, 2026
Alphatec Holdings, Inc. (NASDAQ: ATEC) is a U.S.–based medical-technology firm that develops, manufactures, and markets spinal-surgery implants, instruments, and adjunctive biologics for both domestic and international markets.
The company’s Alpha InformatiX platform bundles the EOS full-body imaging system, the VEA alignment mobile app, the SafeOp Neural InformatiX intra-operative monitoring suite, and the Valence navigation-and-robotics solution, together with the Sigma Prone TransPsoas (PTP) access and positioning systems.
Alphatec’s biologics franchise includes the 3D ProFuse osteoconductive scaffold, several AlphaGRAFT demineralized bone matrix (DBM) formats, the BioCORE synthetic mineral-collagen graft, and the Amnioshield amniotic tissue barrier, all aimed at enhancing fusion outcomes and reducing complications.
Products are sold through a hybrid model of independent sales agents and a direct sales force; the firm was founded in 1990 and is headquartered in Carlsbad, California.
Key industry metrics that shape Alphatec’s outlook: the global spinal-implant market is projected to grow at a 5-6 % CAGR through 2028, driven by an aging population and expanding minimally invasive surgery adoption; ATEC reported FY 2024 revenue of $215 million, a 12 % year-over-year increase, with R&D spending representing roughly 9 % of sales, indicating a commitment to product innovation. Additionally, reimbursement pressure from Medicare’s bundled-payment initiatives remains a material risk for U.S. spine-device makers.
For a data-driven deep-dive into ATEC’s valuation dynamics, you might find the analytics on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -155.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 26.51 > 1.0 |
| NWC/Revenue: 30.08% < 20% (prev 36.00%; Δ -5.93% < -1%) |
| CFO/TA 0.04 > 3% & CFO 35.1m > Net Income -155.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (151.4m) vs 12m ago 5.51% < -2% |
| Gross Margin: 69.23% > 18% (prev 0.69%; Δ 6853 % > 0.5%) |
| Asset Turnover: 94.97% > 50% (prev 76.79%; Δ 18.19% > 0%) |
| Interest Coverage Ratio: -2.85 > 6 (EBITDA TTM -52.2m / Interest Expense TTM 40.2m) |
Altman Z'' -6.89
| A: 0.28 (Total Current Assets 439.8m - Total Current Liabilities 220.8m) / Total Assets 787.2m |
| B: -1.78 (Retained Earnings -1.40b / Total Assets 787.2m) |
| C: -0.15 (EBIT TTM -114.4m / Avg Total Assets 766.6m) |
| D: -1.81 (Book Value of Equity -1.41b / Total Liabilities 775.7m) |
| Altman-Z'' Score: -6.89 = D |
Beneish M -3.18
| DSRI: 0.91 (Receivables 96.8m/83.7m, Revenue 728.0m/572.7m) |
| GMI: 1.00 (GM 69.23% / 69.47%) |
| AQI: 0.96 (AQ_t 0.22 / AQ_t-1 0.23) |
| SGI: 1.27 (Revenue 728.0m / 572.7m) |
| TATA: -0.24 (NI -155.0m - CFO 35.1m) / TA 787.2m) |
| Beneish M-Score: -3.18 (Cap -4..+1) = AA |
What is the price of ATEC shares?
Over the past week, the price has changed by -6.81%, over one month by -36.58%, over three months by -29.16% and over the past year by +21.02%.
Is ATEC a buy, sell or hold?
- StrongBuy: 4
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ATEC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.6 | 78.1% |
| Analysts Target Price | 24.6 | 78.1% |
| ValueRay Target Price | 14.3 | 3.5% |
ATEC Fundamental Data Overview February 03, 2026
P/S = 2.9566
P/B = 191.4653
Revenue TTM = 728.0m USD
EBIT TTM = -114.4m USD
EBITDA TTM = -52.2m USD
Long Term Debt = 495.0m USD (from longTermDebt, last quarter)
Short Term Debt = 71.1m USD (from shortTermDebt, last quarter)
Debt = 591.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 435.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.59b USD (2.15b + Debt 591.2m - CCE 155.7m)
Interest Coverage Ratio = -2.85 (Ebit TTM -114.4m / Interest Expense TTM 40.2m)
EV/FCF = -1000.0x (Enterprise Value 2.59b / FCF TTM -14.0k)
FCF Yield = -0.00% (FCF TTM -14.0k / Enterprise Value 2.59b)
FCF Margin = -0.00% (FCF TTM -14.0k / Revenue TTM 728.0m)
Net Margin = -21.29% (Net Income TTM -155.0m / Revenue TTM 728.0m)
Gross Margin = 69.23% ((Revenue TTM 728.0m - Cost of Revenue TTM 224.0m) / Revenue TTM)
Gross Margin QoQ = 69.87% (prev 69.58%)
Tobins Q-Ratio = 3.29 (Enterprise Value 2.59b / Total Assets 787.2m)
Interest Expense / Debt = 2.18% (Interest Expense 12.9m / Debt 591.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -90.4m (EBIT -114.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.99 (Total Current Assets 439.8m / Total Current Liabilities 220.8m)
Debt / Equity = 51.38 (Debt 591.2m / totalStockholderEquity, last quarter 11.5m)
Debt / EBITDA = -8.34 (negative EBITDA) (Net Debt 435.4m / EBITDA -52.2m)
Debt / FCF = -31.1k (out of range, set to none) (Net Debt 435.4m / FCF TTM -14.0k)
Total Stockholder Equity = 1.49m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.21% (Net Income -155.0m / Total Assets 787.2m)
RoE = -10.4k% (out of range, set to none) (Net Income TTM -155.0m / Total Stockholder Equity 1.49m)
RoCE = -23.03% (EBIT -114.4m / Capital Employed (Equity 1.49m + L.T.Debt 495.0m))
RoIC = -16.63% (negative operating profit) (NOPAT -90.4m / Invested Capital 543.3m)
WACC = 7.03% (E(2.15b)/V(2.74b) * Re(8.49%) + D(591.2m)/V(2.74b) * Rd(2.18%) * (1-Tc(0.21)))
Discount Rate = 8.49% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.39%
Fair Price DCF = unknown (Cash Flow -14.0k)
EPS Correlation: 87.52 | EPS CAGR: 101.5% | SUE: -0.72 | # QB: 0
Revenue Correlation: 98.30 | Revenue CAGR: 29.77% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.00 | Chg30d=-0.003 | Revisions Net=-2 | Analysts=5
EPS next Year (2026-12-31): EPS=0.20 | Chg30d=-0.005 | Revisions Net=-2 | Growth EPS=+666.1% | Growth Revenue=+16.6%